SEC Form 4 · accession 0001179110-17-001102
INVIVO THERAPEUTICS HOLDINGS CORP. · NVIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Ulich
Officer — Chief Scientific Officer
Period of report
Jan 18, 2017
Accepted (ET)
Jan 20, 2017 · 2:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001292519
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.35 | Jan 18, 2017 | A | 150,000 | A | — | Jan 18, 2027 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1This option vests as to 25% of the shares on the first anniversary of the date of grant, and the remaining shares vest thereafter on a monthly basis in 36 equal monthly installments.